Holen Sie sich die Stockscreener-App
17.36
5.08%
0.84
Vorhandelsmarkt:
17.20
-0.16
-0.92%
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa - Yahoo Finance
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment - TipRanks
MLTX SEC FilingsMoonLake Immunotherapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
BVF-linked MoonLake (MLTX) holder trims stake by 3.75M shares - Stock Titan
MoonLake (MLTX) holder BVF sells shares but keeps 22.3% stake - Stock Titan
MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8%Here's Why - MarketBeat
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - msn.com
Form 144 | MoonLake Immunotherapeutics(MLTX.US) 10% Stockholder Proposes to Sell 63.49 Million in Common Stocks - Moomoo
Affiliate sale notice: 3,750,000 shares proposed (NASDAQ: MLTX) - Stock Titan
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics Jumps 9.6% During the Day Amid Positive Developments and Analyst Rating Increases - Bitget
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%Here's What Happened - MarketBeat
MoonLake’s lead asset shows durability in late-stage HS studies - Yahoo Finance
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook - Investing.com
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves - simplywall.st
Research Analysts Issue Forecasts for MLTX Q1 Earnings - MarketBeat
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - Stock Traders Daily
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data - uk.investing.com
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - news.futunn.com
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results - The Clinical Trial Vanguard
MLTX Bounces on Week 40 Trial Data—Is This a Setup for a Gamma Squeeze Before H2 2026 BLA Deadline? - Bitget
MoonLake Immunotherapeutics (MLTX) Is Up 6.5% After Strong Week 40 Sonelokimab HS Data Release – Has The Bull Case Changed? - simplywall.st
AAD26: MoonLake, Incyte highlight deepening responses in long-term HS readouts - FirstWord Pharma
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial - TipRanks
Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa - Dermatology Times
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) An - Bitget
MoonLake Immunotherapeutics Reports Positive Week 40 Results from Phase 3 VELA Trials of Sonelokimab in Moderate-to-Severe Hidradenitis Suppurativa - Quiver Quantitative
Skin disease trial shows 62% response at 40 weeks, no new safety signals - Stock Titan
MoonLake Immunotherapeutics (MLTX) price target increased by 35.37% to 30.19 - MSN
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting - Yahoo Finance
Earnings Risk: What is the earnings history of MoonLake ImmunotherapeuticsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
Buy Signal: What analysts say about MoonLake Immunotherapeutics stock2026 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook By Investing.com - Investing.com India
MoonLake upgraded to Outperform from Underperform at Wolfe Research - TipRanks
HLXC,MLTX Volatility & Greeks - finviz.com
MLTX Upgraded to 'Outperform' by Wolfe Research with Target Pric - GuruFocus
HLXC,MLTX Forecast, Target Price - Finviz
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday - Benzinga
Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - news.futunn.com
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform" - MarketBeat
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook - Investing.com
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):